HelloGold (CURRENCY:HGT) traded up 8.6% against the dollar during the 1-day period ending at 17:00 PM E.T. on July 16th. One HelloGold token can currently be purchased for approximately $0.0089 or 0.00000134 BTC on major exchanges including COSS, HitBTC, Gatecoin and Radar Relay. HelloGold has a market capitalization of $2.35 million and approximately $1,523.00 worth of HelloGold was traded on exchanges in the last 24 hours. Over the last seven days, HelloGold has traded up 7% against the dollar.
Here’s how other cryptocurrencies have performed over the last 24 hours:
Get HelloGold alerts: XRP (XRP) traded 5.1% higher against the dollar and now trades at $0.47 or 0.00007056 BTC. Stellar (XLM) traded 5.8% higher against the dollar and now trades at $0.23 or 0.00003486 BTC. IOTA (MIOTA) traded up 6.8% against the dollar and now trades at $1.08 or 0.00016151 BTC. Tether (USDT) traded 0% lower against the dollar and now trades at $1.00 or 0.00014992 BTC. TRON (TRX) traded up 5.6% against the dollar and now trades at $0.0366 or 0.00000549 BTC. NEO (NEO) traded 8.6% higher against the dollar and now trades at $36.67 or 0.00549695 BTC. Binance Coin (BNB) traded 6.5% higher against the dollar and now trades at $13.14 or 0.00197056 BTC. VeChain (VET) traded 2.3% lower against the dollar and now trades at $1.90 or 0.00028417 BTC. 0x (ZRX) traded down 1.2% against the dollar and now trades at $1.12 or 0.00016741 BTC. Zilliqa (ZIL) traded up 5.5% against the dollar and now trades at $0.0742 or 0.00001113 BTC.HelloGold Profile
Best Warren Buffett Stocks To Watch For 2021: Progenics Pharmaceuticals Inc.(PGNX)
Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company's EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces a standard, automated Bone Scan Index quantification. The Company's clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ((18F) DCFPyL), 1095 and PSMA ADC. The Company's partnered products include Relistor- Subcutaneous injection, Relistor- Oral Tablets and PRO 140.
Azedra
Azedra is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands. The Company has completed enrollment in pivotal Phase IIb clinical trial under Special Protocol Assessment (SPA).
1404 (trofolastat)
The Company's 1404 (trofolastat) is a technetium-99m labeled small molecule, which binds prostate specific membrane antigen (PSMA) and is used as an imaging agent to diagnose and detect localized prostate cancer, as well as soft tissue and bone metastases. The Company has completed a global multi-centered Phase II study assessing the diagnostic accuracy of 1404 imaging in men with high-risk prostate cancer and initiated a multi-center, open-label Phase III trial to determine the sensitivity and specificity of 1404 to correctly identify whether or not patients have clinically prostate cancer
PyL ((18F) DCFPyL)!
The Company's PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer that was discovered and developed at the Center for Translational Molecular Imaging at the Johns Hopkins University School of Medicine. The Company's studies show the uptake of PyL is high in sites of putative metastatic lesions and primary tumors, suggesting the potential for high sensitivity in detecting prostate cancer.
1095
The Company's 1095 is a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule, which is designed to deliver a dose of radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. The Company focuses on initiating a Phase I clinical study.
PSMA ADC
PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer. The Company's Phase II, multicenter clinical trial to assess the safety, tolerability and anti-tumor activity of PSMA ADC, has been completed in both the chemotherapy refractory and chemotherapy naive patients with metastatic castration-resistant prostate cancer (mCRPC).
Relistor
The Company's Relistor is used as a treatment for Opioid-Induced Constipation (OIC), which decreases the constipating side effects induced by opioid pain medications, such as morphine and codeine without diminishing their ability to relieve pain. Relistor-Subcutaneous injection is engaged in the treatment of OIC in patients with non-cancer pain, and is marketed in the United States. Relistor-Oral has completed Phase III clinical trials.
PRO 140
The Company's PRO 140 is a humanized IgG4 monoclonal antibody directed against C-C chemokine receptor type 5 (CCR5), a molecular portal that human immunodeficiency virus (HIV) uses to enter T-cells. PRO 140 blocks the predominant HIV subtype (R5) entry into T-cells by masking this required co-receptor, CCR5. PRO ! 140 has b! een the subject of over seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects.
The Company competes with Merck & Co., Inc., Sucampo Pharmaceuticals, Inc., Shionogi & Co., Theravance, Inc., Johnson & Johnson, Medivation, Inc., Bayer HealthCare Pharmaceuticals Inc. and Aytu Bioscience Inc.
Advisors' Opinion:- [By Logan Wallace]
Get a free copy of the Zacks research report on Progenics Pharmaceuticals (PGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) have received an average recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $13.33.
Best Warren Buffett Stocks To Watch For 2021: Citrix Systems Inc.(CTXS)
Citrix Systems, Inc. designs, develops, and markets technology solutions that deliver information technology services on-demand worldwide. It offers desktop solutions, including Citrix XenDesktop, an integrated desktop virtualization system; Citrix XenApp, an application virtualization solution; and Citrix XenClient, a bare-metal hypervisor, which runs directly on the client device hardware. The company also provides online services, comprising GoToMeeting for online meetings, sales demonstrations, and collaborative gatherings; GoToWebinar, which allows users to host, attend, or participate in a Webinar session; GoToTraining, a training tool that allows trainers to deliver content to various trainees; Integrated HiDef Audio, which provides a audio and Web experience; HiDef Audio that offers audio options with reservationless audio conferencing; GoToAssist, a remote technical-support solution; GoToManage solution for IT management; and GoToMyPC, which offers remote access t o PC and Mac from an Internet-connected computer. In addition, it provides datacenter and cloud solutions, such as Citrix NetScaler, a Web application delivery controller; Citrix Access Gateway, a SSL/VPN that delivers applications with policy-based SmartAccess control; Citrix Repeater Solutions that provide application delivery to branch office users; Citrix XenServer, a platform for managing server virtualization in the datacenter; and Citrix Essentials for XenServer and Hyper-V solution for lab automation, high availability, provisioning, workflow orchestration, and integration with storage systems. Further, the company provides consulting, technical support, and product training and certification services. It markets and licenses its products to enterprise customers through systems integrators, value-added resellers, value-added distributors, and original equipment manufacturers, as well as through the Web. The company was founded in 1989 and is headquartered in Fort Lau derdale, Florida.
Advisors' Opinion:- [By Max Byerly]
Get a free copy of the Zacks research report on Citrix Systems (CTXS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Get a free copy of the Zacks research report on Citrix Systems (CTXS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Qube Research & Technologies Ltd lifted its position in shares of Citrix Systems, Inc. (NASDAQ:CTXS) by 153.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,212 shares of the cloud computing company’s stock after purchasing an additional 1,340 shares during the period. Qube Research & Technologies Ltd’s holdings in Citrix Systems were worth $232,000 as of its most recent SEC filing.
Best Warren Buffett Stocks To Watch For 2021: Banco De Chile(BCH)
Banco de Chile, together with its subsidiaries, provides personal and business baking products and services in Chile and the United States. Its personal banking product line comprises checking accounts, time deposits, money market accounts, demand deposits, now accounts, and prime now accounts. The company also offers lines of credit; credit card products, such as Travel Club, Global Pass, net.card, and PaySafe credit cards; and Internet banking services. Its business banking products and services include financial management products, such as checking accounts, foreign currency accounts, money market accounts, and prime now accounts, as well as a line of credit. In addition, the company provides business Visa, MasterCard, and Travel Club credit cards; and foreign trade services, as well as treasury banking services. Further, it offers various services, including securities brokerage, mutual fund management, factoring, insurance brokerage, financial advisory, and securitiz ation. As of December 31, 2009, the company operated a network of 246 retail branches and 154 Banco CrediChile branches, as well as a network of 1,588 automated teller machines and 415 self-consultation terminals. The company was founded in 1893 and is headquartered in Santiago, Chile.
Advisors' Opinion:- [By Joseph Griffin]
Shares of Banco de Chile (NYSE:BCH) have been given a consensus recommendation of “Sell” by the seven analysts that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a sell recommendation and two have assigned a hold recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $91.00.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Banco de Chile (BCH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Bitcoin Cash (CURRENCY:BCH) traded 3.3% lower against the US dollar during the one day period ending at 23:00 PM E.T. on August 25th. One Bitcoin Cash coin can now be bought for about $520.83 or 0.07863301 BTC on popular exchanges including Mercatox, BTCC, Bit2C and xBTCe. Bitcoin Cash has a market capitalization of $9.02 billion and approximately $268.90 million worth of Bitcoin Cash was traded on exchanges in the last day. Over the last week, Bitcoin Cash has traded down 5.9% against the US dollar.
Best Warren Buffett Stocks To Watch For 2021: XTL Biopharmaceuticals Ltd.(XTLB)
XTL Biopharmaceuticals Ltd., incorporated on March 9, 1993, is a biopharmaceutical company. The Company focuses on the acquisition and development of pharmaceutical drugs for the treatment of medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO).
hCDR1
hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues.
Recombinant Human Erythropoietin
rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
The Company competes with GlaxoSmithKline, Medimmune, Anthera Pharmaceuticals, Immupharma, Bristol-Myers Squibb, Actelion, Merck Serono, Celgene, Invion, Eli Lilly, UCB/Immunomedics, Novartis AG and Abbott Laboratories.
Advisors' Opinion:- [By Lisa Levin]
Check out these big penny stock gainers and losers
Losers Verastem, Inc. (NASDAQ: VSTM) fell 9.7 percent to $4.73 in pre-market trading after announcing a $35 million common stock offering. Evolus, Inc. (NASDAQ: EOLS) shares fell 8 percent to $13.48 in pre-market trading ahead of regulatory update at 8:30 a.m. ET. XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) fell 6.5 percent to $2.01 in pre-market trading after climbing 10.50 percent on Tuesday. Purple Innovation, Inc. (NASDAQ: PRPL) shares fell 5.8 percent to $9.36 in pre-market trading after reporting Q1 results. Blink Charging Co. (NASDAQ: BLNK) fell 5.7 percent to $5.15 in pre-market trading after declining 5.04 percent on Tuesday. RYB Education, Inc. (NYSE: RYB) shares fell 5 percent to $16.39 in pre-market trading following Q1 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares fell 4.4 percent to $4.30 in pre-market trading after rising 40.62 percent on Tuesday. Arbor Realty Trust, Inc. (NYSE: ABR) fell 4.4 percent to $8.92 in pre-market trading after announcing a 5.5 million share common stock offering. Daxor Corporation (NYSE: DXR) fell 4.1 percent to $7.32 in pre-market trading. Ormat Technologies, Inc. (NYSE: ORA) shares fell 3.8 percent to $51.03 in pre-market trading after the company announced plans to restate its Q2, Q3, Q4 and FY 2017 financial statements. Canadian Solar Inc. (NASDAQ: CSIQ) fell 3.5 percent to $16.20 in pre-market trading after reporting Q1 results. CELYAD SA/ADR (NASDAQ: CYAD) shares fell 3.3 percent to $29.70 in pre-market trading after the company reported launch of 1.8 million share offering
Best Warren Buffett Stocks To Watch For 2021: Visteon Corporation(VC)
Visteon Corporation supplies automotive systems, modules, and components to automotive original equipment manufacturers worldwide. The company offers a range of electronics products, including audio/infotainment systems and components, such as base radio/CD head units, infotainment head units, audiophile systems and amplifiers, rear seat family entertainment systems, digital and satellite radios, HD and DAB broadcast tuners, MACH voice link technology, and connectivity solutions for portable devices; driver information systems comprising instrument clusters and displays to assist driving; and powertrain and feature control modules, including controllers for fuel pumps, transfer cases, tuning valves, and security and voltage regulation systems. It also provides electronic climate controls, such as single zone manual electronic and automatic multiple zone modules, as well as integrated audio and climate control assemblies; and lighting products consisting of headlamps, stop lamps, and fog lamps. In addition, the company offers integrated heating, ventilation, and air conditioning systems, which include evaporators, condensers, heater cores, climate controls, compressors, air handling cases, and fluid transport systems; and components and modules that provide cooling and thermal management for the vehicle?s engine and transmission, as well as for batteries and power electronics on hybrid and electric vehicles. Further, it provides interior products, including cockpit modules, which incorporate structural, electronic, climate control, mechanical, and safety components; door panels/modules and interior trim products; and console modules, which deliver storage options. The company was founded in 2000 and is headquartered in Van Buren Township, Michigan.
Advisors' Opinion:- [By Ethan Ryder]
Visteon Corp (NYSE:VC) – B. Riley cut their Q2 2019 earnings per share (EPS) estimates for Visteon in a report issued on Friday, February 22nd. B. Riley analyst C. Horn now forecasts that the auto parts company will post earnings of $1.20 per share for the quarter, down from their prior estimate of $1.35. B. Riley also issued estimates for Visteon’s Q1 2020 earnings at $1.65 EPS, Q2 2020 earnings at $1.55 EPS, Q3 2020 earnings at $1.37 EPS, Q4 2020 earnings at $1.89 EPS and FY2020 earnings at $6.46 EPS.
- [By Shane Hupp]
Visteon Corp (NYSE:VC) – Equities research analysts at B. Riley increased their FY2019 earnings per share estimates for shares of Visteon in a report issued on Tuesday, October 2nd. B. Riley analyst C. Horn now expects that the auto parts company will earn $6.83 per share for the year, up from their previous estimate of $6.00.
No comments:
Post a Comment